Prothena Settles Stock-Drop Suit For $15.75M
Prothena investors have negotiated a $15.75 million settlement with the neuroscience research and development company, which would end claims that it hid salient details of a clinical trial for a new...To view the full article, register now.
Already a subscriber? Click here to view full article